Boehringer nabs FDA's first in­ter­change­abil­i­ty des­ig­na­tion for its Hu­mi­ra com­peti­tor — but will it mat­ter?

The FDA late Fri­day award­ed Boehringer In­gel­heim the first in­ter­change­abil­i­ty des­ig­na­tion for its Hu­mi­ra biosim­i­lar Cyl­te­zo, mean­ing that when it launch­es in Ju­ly 2023, phar­ma­cists will be able to au­to­mat­i­cal­ly sub­sti­tute the Boehringer’s ver­sion for Ab­b­Vie’s mega-block­buster with­out a doc­tor’s in­put.

The des­ig­na­tion will like­ly give Boehringer, which first won ap­proval for Cyl­te­zo in 2017, the leg up on a crowd­ed field of Hu­mi­ra com­peti­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.